Key Takeaways
- Rare disease commercial models start with the patient journey—not the organizational chart.
- Map entry points, diagnostic delay, referral triggers and treatment initiation barriers.
- Centers of Excellence and advocacy networks often sit inside the journey, not outside it.
- Journey insights should shape Medical Affairs, access, field focus and organization design.
Rare disease commercialization should begin with a simple discipline: understand how patients actually move through the healthcare system.
Prevalence estimates create a headline. The patient journey creates the commercial model. In my experience, companies that skip this work often overstate near-term opportunity and underinvest where patients are lost.
This work sits at the center of rare disease commercialization consulting.
What the Journey Should Reveal
Leadership should understand how symptoms first appear, who initially sees the patient, where diagnostic delays occur, what triggers specialist referral, how diagnosis is confirmed, which specialists manage treatment, where Centers of Excellence exist and where treatment access can break down.
Each step can change forecasts, evidence priorities and organizational design.
Networks Inside the Journey
Academic Centers of Excellence, referral specialists and advocacy organizations frequently influence recognition and care far beyond the patients they personally manage. See why Centers of Excellence matter.
Where Access Interrupts Care
Even after a treatment decision, benefit verification, prior authorization, specialty pharmacy coordination and patient support can prevent initiation. Journey mapping should therefore include the access path—not stop at the prescription.
Related: commercial market access strategy.
How to Use Journey Insights
Use the map to pressure-test opportunity assumptions, prioritize educational investment, right-size the organization and sequence launch readiness work. Pair it with the Commercial Readiness Framework.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
